Navigation Links
U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
Date:2/27/2008

s getting topotecan plus thalidomide had a longer cancer-free period after treatment than those receiving topotecan alone, he said. What all of this means is that while thalidomide may not cure ovarian cancer, it may broaden the treatment options available to physicians and provide more hope to women diagnosed with the cancer.

Ovarian cancer is the fifth most common cancer among women. This year in the United States, more than 25,000 women will be diagnosed with ovarian cancer, and about 16,000 will die from it. About 78 percent of women diagnosed with the cancer survive one year after diagnosis, and more than 50 percent survive five years after diagnosis.

The results of this study have led to the development of a new clinical trial at the University of Minnesota that will test the safety and effectiveness of a newer member of the class of drugs containing thalidomide properties for treatment of recurrent ovarian cancer.


'/>"/>

Contact: Sara E. Buss
buss@umn.edu
612-626-7037
University of Minnesota
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Minnesota Registered Nurses Promote Law to Improve Patient Care and Address Health Care Costs
2. New Report Offers Comprehensive Look at Mental Health in Minnesota
3. Mitchell Medical and Jopari Solutions Team up to Offer eBilling Compliance Services to Automobile Property & Casualty Insurance Carriers to Meet New Minnesota Requirements
4. HealthPartners Contracts with SEIU Healthcare Minnesota Expires with No Agreement on New Contracts
5. New Survey Finds 76 Percent of Minnesotans Support Smoke-Free Law
6. Minnesotans Health Stuck in Idle From Inactivity, Unhealthy Eating
7. Sudden Cardiac Arrest Association Launches Two Minnesota Affiliates
8. QUITPLAN(R) Services Can Help Minnesotans Kick Tobacco Habit for New Year
9. American Lung Association Offers Biodiesel Scholarship to Minnesota High School Seniors
10. Decreasing access to cigarettes for youth in the Minnesota Adolescent Community Cohort Study
11. ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
(Date:11/24/2009)... , This release is available in French and Sp...Granada have found a suicide gene, called ,gene E...d from breast, lung and colon cancer, and prevents...that its use to fight cancer can reduce the potent... more effective treatment for cancer. , This res...
(Date:11/24/2009)... Kids from less-affluent families are at higher r...ealthDay News) -- Although children from poorer fa...r rate of accidental injuries, child care could ac...search suggests. , In the report, published onl...mmunity Health , researchers looked at a study of ...
(Date:11/24/2009)... , New York personal inju...ne to have the number of a personal injury attorne...lands in a local Long Island backyard. , ...2009 -- New York personal injury attorney David ...er that everyone should have the number of a perso...
(Date:11/24/2009)... , Several Tips to Get a ...tion , Bethesda, Md. (Voc...between 8,000-10,000 steps a day—but that nu...son. As expert and rookie travelers alike continue...y to forget that the feet often bear the brunt of ...
(Date:11/24/2009)... ,, RESTON,Va.,Nov.24/PRNewswire/--LincolnCo...oastofMainewithtwosmallhospitalsandretirementcommu...e. ,, "Ifyou,reanITpersonandyou,renotgettingsuc...ts,VicePresidentofInformationServicesatLCH.Asisthe...ghtforLCH,butBettsknewheneededabackupredesigntopro...
Breaking Medicine News(10 mins):Health News:Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage 2Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 2Health News:A New York Neighborhood Gets Hit Hard When A Piece Breaks Off A Plane 3Health News:Keep Holiday Travel Foot-Friendly 2Health News:Keep Holiday Travel Foot-Friendly 3Health News:Replay 4 Customer Takes Risk, Fights for Budget to Protect Information Systems 2
...er families in North Carolina living in inadequate...s, disease and overcrowding// which in turn can af...ding to new research by Wake Forest University Sch...o improve these conditions because of the vital ro...
...l of child healthcare unveiled yesterday, gives yo...cotland for the first time// . Giving priority to ...ork for the children similar to that already laid ...ng people. Majority of NHS staff would also be tra...
..., from Oswestry, a patient with breast cancer in E...nts in Welsh are given free drug treatment// at a ...ent for Herceptin in full, unlike the Shropshire P...hire MP Owen Paterson said that breast cancer pati...
...s, the one that causes mononucleosis, may be a cau...ts with high levels of antibodies//, according to ...will appear later in June 2006 print issue of Arch...e disease that affects the central nervous system,...
...archers from the University of London, the cause o...nication between brain areas//. And the reason for... links between brain areas may mean that people wi...utism Spectrum Disorder (ASD) while the other 16 d...
...new study, funded by Athersys Inc., a U.S. biophar...iate professor of neurology// at the Medical Colle...lanted human bone marrow cells into the brains of ...ir findings on Friday at the American Academy of N...
Other Medicine News:Health News:Poor Housing May lead to Poor Health 2Health News:Children Health Care To Be Given Priority 2Health News:Cancer Patients Protest For Free Drug Treatment 2Health News:Epstein-Barr Virus May Be May Be A Cause For Multiple Sclerosis 2Health News:Lack Of Communication Between Brain Areas Can Cause Autism 2Health News:Neurological Damage Can Be Reduced By Stem Cell Transplants 2
(Date:11/24/2009)..., XI,AN,China,Nov.24/PRNewswire-Asia/--HuifengBio-...GB),aleadingdeveloperandproducer,ofplantextractsan...,nutraceuticalandfoodproductioninXi,an,China,today...26%increaseinrevenues. , Revenuesforthequarte...,147,or26%,from$3,534,623forthesamequarterin2008.N...
(Date:11/24/2009)..., SANDIEGO,Nov.24/PRNewswire-FirstCall/--Neurocrin...KevinGorman,PresidentandChiefExecutiveOfficerofNeu...PiperJaffrayHealthCareConferenceinNewYork. ,, T...at4:30p.m.EasternTime(ET)/1:30p.m.PacificTime(PT)....accessedontheCompany,swebsiteat http://www.neurocr...
(Date:11/24/2009)..., ,, ANDOVER,Mass.,Nov.24/PRNewswire/--Visag...icusLtd.(ASX:PME),willbeintroducingVisage®7,t...n,attheAnnualConferenceoftheRadiologicSocietyofNor...o,IL. ,, Visage®7deliversnewlevelsofversat...b-specialists,andreferringphysicians.TheVisage7Uni...
Breaking Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Visage Imaging Introduces Visage(R) 7 for Windows and Mac OS X 2HOYA ConBio Announces Educational Alliance with LVI Global Australia 55683 1HOYA ConBio Announces Educational Alliance with LVI Global Australia 55683 2Painless Bruise free Dermal Filler Injections 55680 1Painless Bruise free Dermal Filler Injections 55680 2BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 1BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 2BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 3
...nc. (AMEX: SYI ) announced today, dosing of the f...clinical trial of alagebrium,(ALT-711), a novel co...d-product (AGE)-cross-link breaker, in patients wi...dy (Double- blind, placebo-controlled,randomized t...ium) is,designed to measure the effect of alagebri...
...oReagents, a leading global antibody manufacturer,...t Medica in Dusseldorf, Germany. Medica is the wo...0,visitors expected from all parts of the globe. "...gents. The exposure is global, and it is a wonderf...with our international,business partners and distr...
Other Medicine Technology:Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 2Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 3Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 4ABR-Affinity BioReagents to Exhibit in the U.S. Pavilion at Medica, November 14 - 17, 2007 2
Glucose UV Liquidplus
Glucose Color Liquidplus Reagent
Glucose (Oxidase)
Glucose (Hexokinase)
Medicine Products: